⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8788678 | 0.73 | — | — | |
| SCHEMBL9044554 | 0.73 | — | — | |
| SCHEMBL8789877 | 0.73 | — | — | |
| SCHEMBL8790015 | 0.70 | — | — | |
| SCHEMBL920451 | 0.60 | KMT2A (0.31) | — | |
| SCHEMBL174054 | 0.59 | HTR6 (0.42) | — | |
| SCHEMBL4166916 | 0.58 | HTR6 (0.41) | — | |
| SCHEMBL8725945 | 0.58 | — | — | |
| SCHEMBL9059294 | 0.57 | — | — | |
| SCHEMBL127850 | 0.57 | HTR6 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322726-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| EP-3575288-B1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-27 | — | — | EP | disclosed |
| US-11008306-B2 | Quinazolines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200255407-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-13 | — | — | US | disclosed |
| US-10676460-B2 | Quinazolines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-09 | — | — | US | disclosed |
| EP-3575288-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | Bristol-Myers Squibb Company (US) | 2019-12-04 | — | — | EP | disclosed |
| EP-3124475-B1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20190144426-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-05-16 | — | — | US | disclosed |
| EP-2411793-B1 | pH METER DEVICE | PARKER HANNIFIN CORP (US) | 2019-05-08 | — | — | EP | disclosed |
| EP-2459565-B1 | SAXITOXIN DERIVATIVES, METHODS AND COMPOSITIONS FOR STUDYING, IMAGING, AND TREATING PAIN | UNIV LELAND STANFORD JUNIOR (US) | 2018-05-02 | — | — | EP | disclosed |
| US-20050250783-A1 | Fused heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-10 | — | — | US | disclosed |
| WO-2005105096-A2 | FUSED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-10 | — | — | WO | disclosed |
| US-20050202459-A1 | Intercalation-mediated synthesis of polymers | GEORGIA TECH RESEARCH CORPORATION | 2005-09-15 | — | — | US | disclosed |
| US-20050171156-A1 | Prodrugs of potassium channel inhibitors | ICAGEN, INC. | 2005-08-04 | — | — | US | disclosed |
| WO-2005044189-A2 | DIALYSATES AND METHODS AND SYSTEMS RELATED THERETO | EMORY UNIVERSITY (US) | 2005-05-19 | — | — | WO | disclosed |
| US-20040063687-A1 | Heterocyclic dihydropyrimidine compounds | ATWAL KARNAIL S (US) | 2004-04-01 | — | — | US | disclosed |
| US-6706720-B2 | TREATMENT OF ARRHYTHMIA; INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-16 | — | — | US | disclosed |
| US-20030022890-A1 | Heterocyclic dihydropyrimidine compounds | PEDESTRIAN CONCEPTS LLC | 2003-01-30 | — | — | US | disclosed |
| EP-1237891-A1 | HETEROCYCLIC DIHYDROPYRIMIDINES AS POTASSIUM CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001040231-A1 | HETEROCYCLIC DIHYDROPYRIMIDINES AS POTASSIUM CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-06-07 | — | — | WO | disclosed |